156 related articles for article (PubMed ID: 27469379)
21. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
22. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract][Full Text] [Related]
23. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
[TBL] [Abstract][Full Text] [Related]
24. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
[TBL] [Abstract][Full Text] [Related]
25. The life and times of low-grade serous carcinoma of the ovary.
Gershenson DM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714500
[TBL] [Abstract][Full Text] [Related]
26. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
27. The changing view of high-grade serous ovarian cancer.
Berns EM; Bowtell DD
Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
[TBL] [Abstract][Full Text] [Related]
28. Low-grade serous carcinoma: new concepts and emerging therapies.
Romero I; Sun CC; Wong KK; Bast RC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):660-6. PubMed ID: 23707670
[TBL] [Abstract][Full Text] [Related]
29. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
30. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
[TBL] [Abstract][Full Text] [Related]
31. Acquired chemotherapy resistance in ovarian cancer.
Christie EL; Bowtell DDL
Ann Oncol; 2017 Nov; 28(suppl_8):viii13-viii15. PubMed ID: 29232469
[TBL] [Abstract][Full Text] [Related]
32. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
33. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
34. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
36. Ovarian low-grade serous carcinoma: a comprehensive update.
Diaz-Padilla I; Malpica AL; Minig L; Chiva LM; Gershenson DM; Gonzalez-Martin A
Gynecol Oncol; 2012 Aug; 126(2):279-85. PubMed ID: 22555104
[TBL] [Abstract][Full Text] [Related]
37. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
38. MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
Gershenson DM; Gourley C; Paul J
J Clin Oncol; 2020 Nov; 38(32):3731-3734. PubMed ID: 32897828
[No Abstract] [Full Text] [Related]
39. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
